| Name | Title | Contact Details |
|---|
Chesapeake Bank is a community bank located in Kilmarnock, Virginia, serving the Northern Neck and Middle Peninsula regions. Established in April 1900 as Lancaster National Bank, it was founded to support local watermen, oystermen, and fishermen. Over the years, the bank has expanded its services to include farmers and various local businesses, adapting to the needs of the community. The bank offers a variety of banking services, including personal banking options like checking and savings accounts, personal loans, and credit cards. For businesses, Chesapeake Bank provides loans, lines of credit, and cash management services. Additionally, it offers investment services through Chesapeake Wealth Management. Known for its community-focused approach, Chesapeake Bank emphasizes treating customers like neighbors and actively engages in local initiatives.
Seimitsu has served the Savannah community since 1984, providing full-service information technology solutions to an extensive range of businesses and organizations.
Modern management software for gyms, martial arts schools, yoga studios and membership clubs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com